Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from NLS Pharmaceutics ( (NLSP) ).
On September 10, 2025, NLS Pharmaceutics and Kadimastem announced that the SEC declared effective their registration statement related to a proposed merger. This marks the final regulatory step needed to close the merger, which will result in a new entity, NewCelX Ltd., combining cell therapy and small-molecule expertise. The merger is expected to enhance the companies’ global reach and diversify their therapeutic pipeline, with implications for stakeholders in terms of increased market access and expanded research capabilities.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders. Kadimastem Ltd. is a clinical-stage cell therapy company working on treatments for neurodegenerative diseases and diabetes.
Average Trading Volume: 215,134
Technical Sentiment Signal: Sell
Current Market Cap: $7.12M
For detailed information about NLSP stock, go to TipRanks’ Stock Analysis page.